TMRW Life Sciences, Inc. — SEC Form D Filing

TMRW Life Sciences, Inc. filed an SEC Form D on April 24, 2026, reporting $38.36M raised in Health Care.

Form D filing details

Filing
SEC Form D
Filing date
April 24, 2026
Amount reported
$38.36M
Round stage
Seed
Industry
Health Care
Website
https://www.tmrwlifesciences.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

With the increasing demand for fertility treatments, clinics require new solutions to optimize and safely scale the management and storage of frozen eggs and embryos.

Solution

TMRW provides an FDA-cleared automated platform for managing frozen eggs and embryos, featuring RFID tracking, a digital database, 24/7 monitoring, and safe transport solutions to ensure reliability and safety.

Why now

The increasing number of people using assisted reproductive technology has created a demand for reliable and efficient storage solutions for frozen eggs and embryos.

Verdict

Investors leaned in at this point because TMRW's solution addressed an urgent need for efficient fertility management, capitalizing on the burgeoning assisted reproductive technology market. They were betting on the premise that clinics would prioritize automation and safety enhancements in an increasingly competitive landscape. This cleared because the urgency of scalable solutions resonated strongly, not because existing manual processes were inherently faltering.

Source: SEC EDGAR Form D filing